On October 28, 2024, Imunopharm Technology Co., Ltd. (referred to as "Imunopharm") announced that the new generation CAR-T drug ZM001 injection (referred to as "ZM001"), developed in collaboration with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (referred to as "Sun-Novo"), for the treatment of Systemic Lupus Erythematosus (SLE), has received a clinical trial approval notice from the National Medical Products Administration (NMPA).

This approval marks a significant breakthrough for Imunopharm in the field of CAR-T cell therapy for autoimmune diseases. It is the company's first clinical approval for a CAR-T cell drug to treat an autoimmune disease and is also the seventh CAR-T cell drug to receive a clinical trial approval.